Firefly Neuroscience, Inc., a medical technology and artificial intelligence company, provides neuroscientific solutions that improve outcomes for patients with mental illnesses and neurological disorders. The company is headquartered in Toronto, Canada.
| Revenue (TTM) | $1.80M |
| Gross Profit (TTM) | 802,000 |
| EBITDA | $-8.72M |
| Operating Margin | -384.10% |
| Return on Equity | -68.10% |
| Return on Assets | -34.80% |
| Revenue/Share (TTM) | $0.12 |
| Book Value | $0.94 |
| Price-to-Book | 1.23 |
| Price-to-Sales (TTM) | 17.53 |
| EV/Revenue | 9.41 |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 71.90% |
| Shares Outstanding | $15.69M |
| Float | $14.02M |
| % Insiders | 28.12% |
| % Institutions | 10.46% |
Volatility is currently expanding
– Partnership will introduce NeuroSigma's second-generation Monarch eTNS ® System to Firefly's nationwide network of Evoke™ clinicians –
– This integration of Firefly's FDA 510(k)-cleared, AI-powered EEG/ERP technology follows Radial's August 2026 acquisition of the management services organization supporting Mindful Health Solutions, forming the country's largest brain medicine clinical network –
KENMORE, N.Y., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence ("AI") company advancing precision neuroscience, today announced a close to four-fold (291%) year-over-year increase in Transcranial Magnetic Stimulation (“TMS”) center customer clinical assessments using its U.S. Food and Drug Administration (“FDA”) 510(k)-cleared, AI-powered EEG/ERP platform, Evoke™.
– FDA Advisory Committee voted to recommend easing compounding restrictions for six peptides, including Epitalon and Semax, late last week –
– Comes just weeks after Firefly confirmed its active public-private partnership with the U.S. Department of War – KENMORE, N.Y, June 02, 2026 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company advancing precision neuroscience, today announced the identification of a novel electrophysiological biomarker for Post-Traumatic Stress Disorder (“PTSD”) using brain scans collected on its FDA-510(k)-cleared Evoke System. The biomarker discovery emanates partly from Firefly's previously announced public-private partnership with the U.S. Department of War (“DoW”) to support the assessment and treatment of active-duty U.S. service members and veterans suffering from PTSD and/or Traumatic Brain Injury (“TBI”).
- Firefly's total brain scan volumes have increased sequentially by higher percentages in each of the past four quarters -
Firefly's AI-powered, FDA-cleared EEG/ERP Technology is Being Deployed to Support Assessment and Treatment of PTSD and TBI in U.S. Service Members
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on AIFF and any ticker you trade — then tracks every position and per-strategy win rate.
